{"entity":{"id":"flutamide","kind":"drug","name":"Flutamide","aka":[],"tldr":"Flutamide was the first tablet to block testosterone at the prostate cancer cell. It is taken with an injection that stops testosterone production, but newer drugs have largely replaced it.","summary":"Flutamide was approved in 1989 for use with LHRH agonists in stage B2 to C prostate cancer (with radiotherapy) and in stage D2 metastatic disease, introducing combined androgen blockade. Trials in the 1980s and 1990s showed at best a small survival gain over castration alone, and bicalutamide, then enzalutamide, apalutamide and darolutamide superseded it because of three-times-daily dosing, diarrhoea and a boxed warning for hepatotoxicity including fatal liver failure. It is still listed for antiandrogen flare cover at the start of LHRH agonist therapy.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Flutamide","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=flutamide"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/flutamide"}],"tags":["nci-list","generic"],"related":["bicalutamide"],"cancers":["prostate"],"sections":[],"technologies":["androgen-deprivation"],"targets":["androgen-receptor"],"drugs":[],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00104741","nct00002881","nct03678025"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Eulexin (historic)","modality":"Non-steroidal antiandrogen (first generation)","mechanism":"Competitive antagonist of the androgen receptor; its active metabolite hydroxyflutamide blocks androgen binding and nuclear translocation in prostate cells.","approvals":[{"region":"US","year":1989,"indication":"Locally advanced (B2 to C) and metastatic (D2) prostate cancer in combination with an LHRH agonist"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/flutamide/","neighbours":{"drug":[{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/"},{"id":"nilutamide","kind":"drug","name":"Nilutamide","route":"/drugs/nilutamide/"}],"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"dart-01-05-gicor","kind":"trial","name":"DART 01/05 GICOR","route":"/trials/dart-01-05-gicor/"},{"id":"nct00002881","kind":"trial","name":"Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer","route":"/trials/nct00002881/"},{"id":"nct00003653","kind":"trial","name":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","route":"/trials/nct00003653/"},{"id":"nct00004054","kind":"trial","name":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","route":"/trials/nct00004054/"},{"id":"nct00002633","kind":"trial","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00002633/"},{"id":"nct00567580","kind":"trial","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","route":"/trials/nct00567580/"},{"id":"nct00936390","kind":"trial","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00936390/"},{"id":"rtog-9202","kind":"trial","name":"RTOG 92-02","route":"/trials/rtog-9202/"},{"id":"spcg-7","kind":"trial","name":"SPCG-7/SFUO-3","route":"/trials/spcg-7/"},{"id":"nct03678025","kind":"trial","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","route":"/trials/nct03678025/"},{"id":"nct00104741","kind":"trial","name":"Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer","route":"/trials/nct00104741/"},{"id":"nct04513717","kind":"trial","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","route":"/trials/nct04513717/"}]}}